Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 16/20 | 0.67 |
| ▸ | PPARA | Q07869 | 11/20 | 0.67 |
| ▸ | PPARG | P37231 | 8/20 | 0.67 |
| ▸ | FFAR1 | O14842 | 8/20 | 0.56 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4243266 | 0.85 | PPARD (0.63) | PPARDPPARAPPARGFFAR1CHRM5 | |
| SCHEMBL6238901 | 0.81 | PPARD (1.00) | PPARDPPARAPPARGFFAR1CHRM5 | |
| SCHEMBL3372315 | 0.78 | PPARD (0.72) | PPARDPPARAPPARGFFAR1CHRM5 | |
| SCHEMBL3369920 | 0.76 | PPARD (0.70) | PPARDPPARAPPARGFFAR1CHRM5 | |
| SCHEMBL6236634 | 0.76 | PPARD (1.00) | PPARDPPARAPPARGFFAR1 | |
| SCHEMBL3374163 | 0.76 | PPARD (0.69) | PPARDPPARAPPARGFFAR1CHRM5 | |
| SCHEMBL4251717 | 0.76 | PPARD (0.49) | PPARDPPARAPPARGFFAR1 | |
| SCHEMBL3374589 | 0.75 | PPARD (0.68) | PPARDPPARAPPARGFFAR1CHRM5 | |
| SCHEMBL4118356 | 0.75 | PPARD (1.00) | PPARDPPARAPPARGFFAR1CHRM5 | |
| SCHEMBL4830322 | 0.75 | PPARD (0.77) | PPARDPPARAPPARGFFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090012069-A1 | Novel Antidiabetic Compounds | CADILA HEALTHCARE LIMITED (IN) | 2009-01-08 | — | — | US | claimed |
| US-20090012069-A1 | Novel Antidiabetic Compounds | CADILA HEALTHCARE LIMITED (IN) | 2009-01-08 | — | — | US | disclosed |
| EP-1781633-A1 | NOVEL ANTIDIABETIC COMPOUNDS | CADILA HEALTHCARE LIMITED (IN) | 2007-05-09 | — | — | EP | disclosed |
| WO-2006018855-A1 | NOVEL ANTIDIABETIC COMPOUNDS | CADILA HEALTHCARE LIMITED (IN) | 2006-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012069-A1 | Novel Antidiabetic Compounds | GPR119, SLC5A1, SLC5A2 | PPARD 54/4885PPARA 145/4885PPARG 76/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.